Cargando…

RBM20-Related Cardiomyopathy: Current Understanding and Future Options

Splice regulators play an essential role in the transcriptomic diversity of all eukaryotic cell types and organ systems. Recent evidence suggests a contribution of splice-regulatory networks in many diseases, such as cardiomyopathies. Adaptive splice regulators, such as RNA-binding motif protein 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koelemen, Jan, Gotthardt, Michael, Steinmetz, Lars M., Meder, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468976/ https://www.ncbi.nlm.nih.gov/pubmed/34575212 http://dx.doi.org/10.3390/jcm10184101

Ejemplares similares

iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy
por: Briganti, Francesca, et al.
Publicado: (2020)

Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3
por: Kornienko, Julia, et al.
Publicado: (2023)

New Insights in RBM20 Cardiomyopathy
por: Lennermann, D., et al.
Publicado: (2020)

Alternative Splicing Regulator RBM20 and Cardiomyopathy
por: Watanabe, Takeshi, et al.
Publicado: (2018)

Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options
por: Migliore, Federico, et al.
Publicado: (2021)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy
por: Hinze, Florian, et al.
Publicado: (2016)

Cardiomyopathy: RBM20 mutations impair splicing of cardiac genes
Publicado: (2012)

RBM20 mutations in left ventricular non‐compaction cardiomyopathy
por: Gaertner, Anna, et al.
Publicado: (2020)

Molecular basis of titin exon exclusion by RBM20 and the novel titin splice regulator PTB4
por: Dauksaite, Vita, et al.
Publicado: (2018)

Pathogenic variant of RBM20 in a multiplex family with hypertrophic cardiomyopathy
por: Inagaki, Natsuko, et al.
Publicado: (2022)

Disruption of the nuclear localization signal in RBM20 is causative in dilated cardiomyopathy
por: Zhang, Yanghai, et al.
Publicado: (2023)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Editorial: Cardiomyopathies: Current Treatment and Future Options
por: Peters, Stefan
Publicado: (2020)

RBM20 phosphorylation and its role in nucleocytoplasmic transport and cardiac pathogenesis
por: Zhang, Yanghai, et al.
Publicado: (2022)

Dilated cardiomyopathy caused by a pathogenic nucleotide variant in RBM20 in an Iranian family
por: Malakootian, Mahshid, et al.
Publicado: (2022)

Familial dilated cardiomyopathy with RBM20 mutation in an Indian patient: a case report
por: Das, Soumi, et al.
Publicado: (2021)

Drug discovery with an RBM20 dependent titin splice reporter identifies cardenolides as lead structures to improve cardiac filling
por: Liss, Martin, et al.
Publicado: (2018)

The Combined Human Genotype of Truncating TTN and RBM20 Mutations Is Associated with Severe and Early Onset of Dilated Cardiomyopathy
por: Gaertner, Anna, et al.
Publicado: (2021)

A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fibrillation in mice
por: Ihara, Kensuke, et al.
Publicado: (2020)

Sickle Cell Disease: Current Understanding and Future Options
por: Varelas, Christos, et al.
Publicado: (2023)

Muscle-Specific Mis-Splicing and Heart Disease Exemplified by RBM20
por: Rexiati, Maimaiti, et al.
Publicado: (2018)

SR Protein Kinases Regulate the Splicing of Cardiomyopathy-Relevant Genes via Phosphorylation of the RSRSP Stretch in RBM20
por: Sun, Mingming, et al.
Publicado: (2022)

I536T variant of RBM20 affects splicing of cardiac structural proteins that are causative for developing dilated cardiomyopathy
por: Yamamoto, Takuma, et al.
Publicado: (2022)

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy
por: Muratore, Claudio A, et al.
Publicado: (2010)

The Emerging Role of the RBM20 and PTBP1 Ribonucleoproteins in Heart Development and Cardiovascular Diseases
por: Fochi, Stefania, et al.
Publicado: (2020)

Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options
por: Bremova-Ertl, Tatiana, et al.
Publicado: (2023)

Narcolepsy: current treatment options and future approaches
por: Billiard, Michel
Publicado: (2008)

Current Options and Future Perspectives in the Treatment of Dyslipidemia
por: Muscoli, Saverio, et al.
Publicado: (2022)

Current and Future Therapeutical Options in Alport Syndrome
por: Reiterová, Jana, et al.
Publicado: (2023)

Hotspots 2.0: Toward an integrated understanding of stressors and response options
por: Khan, Ahmed S., et al.
Publicado: (2018)

Pathophysiological Defects and Transcriptional Profiling in the RBM20(-/-) Rat Model
por: Guo, Wei, et al.
Publicado: (2013)

Peripartum cardiomyopathy: current management and future perspectives
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2015)

Fabry Cardiomyopathy: Current Practice and Future Directions
por: Yim, Jeffrey, et al.
Publicado: (2021)

Current and future treatment options for polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2015)

Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model
por: Wyles, SP, et al.
Publicado: (2016)

Current and future options for the management of phantom-limb pain
por: Knotkova, Helena, et al.
Publicado: (2012)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Current and Possible Future Therapeutic Options for Huntington’s Disease
por: Ferguson, Mackenzie W., et al.
Publicado: (2022)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_68thke69c6md9aiu8jj70uljc5